Resmed Inc. RMD

NYS: RMD | ISIN: US7611521078 16/01/2025

237,13 USD (+1,61%)

(+1,61%) 16/01/2025

Grafiek Resmed Inc.

Grafiek Resmed Inc.

1 dag1d 1,61%
1 week1w 1,42%
1 maand1m -2,26%
3 maanden3m -1,03%
6 maanden6m 15,14%
1 jaar1j 38,91%
5 jaar5j 47,68%

donderdag 30 januari 2025, 22:05

Kwartaalcijfers (2de kwartaal)

Resmed Inc. in het nieuws

Toon enkel gratis nieuws

10 september 2024 · Vaping Expected to Increase COPD Health and Economic Burden by 2050 · Persbericht

10 juni 2024 · PAP Therapy Reduces Hospitalizations by 31% and ER Visits by 23% for People with Obstructive Sleep Apnea and Comorbid Insomnia · Persbericht

15 maart 2024 · ResMed's 2024 Global Sleep Survey Uncovers a World in Sleep Crisis · Persbericht

9 november 2023 · ResMed Adopts New Operating Model to Accelerate Long-term Growth · Persbericht

6 oktober 2023 · Thinking about trading options or stock in Apple, Super Micro Computer, Pioneer Natural Resources, Shoals Technologies Group, or Resmed? · Persbericht

5 juli 2023 · ResMed Acquires Somnoware, a Leader in Digital Sleep and Respiratory Care Diagnostics Software · Persbericht

8 juni 2023 · PAP Adherence Lowers ER Visits 24-36% in 1 Year for People with Sleep Apnea and Heart Failure: ResMed Studies Presented at SLEEP · Persbericht

25 mei 2023 · 3 World-Renowned Sleep Apnea Experts Present New Benefits of PAP Therapies at ATS 2023 · Persbericht

2 mei 2023 · ResMed Appoints Michael Rider its Next Global General Counsel, Dawn Haake its First Chief Quality Officer · Persbericht

30 maart 2023 · ResMed Chief Administrative Officer and Global General Counsel to Retire · Persbericht

Profiel Resmed Inc.

Gezondheidstechnologie

Medische Specialiteiten

Productie van medische instrumenten

Website: www.resmed.com

Hoofdzetel: San Diego, California Verenigde Staten

CEO: Michael Farrell

Werknemers: 5.138

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe